Robert W Townsend*
Independent Unaffiliated Neurobiochemistry Researcher/Author, Clinical Mental Health Specialist, and Private Clinic Proprietor, USA
*Corresponding Author: Robert W Townsend, Independent Unaffiliated Neurobiochemistry Researcher/Author, Clinical Mental Health Specialist, and Private Clinic Proprietor, USA.
Received: October 11, 2022; Published: November 08, 2022
Introduction: Background: Discoveries in this study can significantly improve the health and quality of life of over ten million Parkinson’s- affected people. Clinicians prescribe AntiParkinsonian medications to treat Parkinson’s illnesses and Parkinsonism. AntiParkinsonian Carbidopa-Levodopa, Ropinirole, and Pramipexole commonly cause progressive neural damage (augmentation) and adverse reactions such as excessive sedation, sudden passing out, and slowed cognition. This study presents a neurobiochemistry analysis regarding the world’s first long-term treatment of Parkinson’s with Methylphenidate. The neurobiochemistry analysis in this study describes and explains how Methylphenidate adjunctive therapy counteracts the adverse effects of AntiParkinsonians and how Methylphenidate monotherapy controls motor and non-motor symptoms, strengthens neural tissues, sustains alertness and cognition, and slows progressive worsening. Clinical uses of Methylphenidate rarely cause side effects and they are virtually always minor. Methylphenidate is prescribed to millions of children as young as 6 years.
Methods: This article analyzes the neurobiochemistry of Methylphenidate vs. AntiParkinsonian therapy based on a review of over 400 published articles and a 17-year treatment for severe Parkinson’s/Parkinsonism with nine years of AntiParkinsonians followed by eight years of Methylphenidate. The recipient, Dr R, is a 66-year-old PhD American male who is a published Researcher. At age-55 he was documented as disabled and needing medications to function. At age- 58 his illness and the adverse effects of APs jointly caused total disability for which there was no medication or remedy. Thus he conceived and designed the world’s first long-term Methylphenidate treatment of Parkinson’s. He implemented it with the cooperation of a prescribing Physician.
Results: Initial experimentation found that 30 mg doses of Methylphenidate overcame the adverse effects of adjunctive AntiParkinsonians. Continued experimentation later found that 20 mg doses of Methylphenidate monotherapy controlled Parkinson’s illness-symptoms better than AntiParkinsonians. An experimental 3-hour dosing schedule resulted in uninterrupted efficacy during transitions between doses. Efficacy duration was extended to 16 hours by adding sequential doses every three hours. A 25 mg dose upon waking overcame residual morning grogginess from high-dose AntiParkinsonians at bedtime that gave good sleep. Six years of gradual titration resulted in an optimally effective daily regimen of: [dose-1, 3-hour MPH-IR 25 mg], [dose-2, 6-hour MPH-ER 40 mg], [dose-3, 3-hour MPH-IR 20 mg], [dose-4, 3-hour MPH-IR 20 mg], [bedtime 2 tabs Carb-Levo 10/100 mg, 2 tabs Carb-Levo ER 25/100 mg, and 2 tabs Pramipexole 0.25 mg].
Conclusion: Clinicians can replace diurnal AntiParkinsonians with diurnal Methylphenidate in order to provide safer and more effective long-term treatment of Parkinson’s illnesses and Parkinsonism.
Keywords:AntiParkinsonians; Dopamine; Methylphenidate; Narcolepsy; Parkinson’s; Pramipexole
Citation: Robert W Townsend. “Biochemistry of Methylphenidate in Long-term Treatment of Parkinson’s". Acta Scientific Neurology 5.12 (2022): 12-32.
Copyright: © 2022 Robert W Townsend. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
+91 9182824667
Open Access by
Acta Scientific is licensed under a Creative Commons Attribution 4.0 International License
Based on a work at https://actascientific.com
ff
